SaaS Metrics
Pharmaceutical Innovation, Regulatory Scrutiny
Oral Administration
AI Synthesis & Market Narrative
Oral administration remains a key focus for pharmaceutical innovation, with new drugs targeting bradykinin-mediated diseases and inflammatory myopathies. Concurrently, regulatory bodies are increasing scrutiny on unapproved over-the-counter drugs, emphasizing compliance.
Correlated Linguistic Patterns
["Oral drug development"
"Bradykinin B2 antagonists"
"TYK2\/JAK1 inhibitors"
"Psoriasis treatment"
"Unapproved OTC drugs"]
Driving Media Context
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece...
Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies
Spherix Global Insights highlights rising enthusiasm for Priovant’s TYK2/JAK1 inhibitor alongside continued dissatisfaction with current treatment approaches...
Mitochondrial oxidative phosphorylation inhibition by 9α,11α-dihydroxy-kaurenoic acid promotes ROS-associated apoptosis and suppresses cancer stemness in non-small cell lung cancer
Scientific Reports - Mitochondrial oxidative phosphorylation inhibition by 9α,11α-dihydroxy-kaurenoic acid promotes ROS-associated apoptosis and suppresses c...
GSC Products, LLC - 729653 - 05/18/2026
Unapproved New Drugs/Misbranded/OTC
Two-dimensional GeTe nanosheets for psoriasis through modulation of macrophage activation and psoriatic inflammation
Biomater. Sci., 2026, Advance ArticleDOI: 10.1039/D5BM01657F, PaperJieun Han, Ju-Won Kim, In Kang, Sun-Mi Lee, Yong-Beom ParkTwo-dimensional germanium tellur...
Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral...
Global Alzheimer's Therapeutics Market Expands at 9.3% CAGR as Biologics and Early Diagnosis Transform Dementia Care
NEWARK, Del., May 20, 2026 /PRNewswire/ -- The global Alzheimer's Therapeutics Market is projected to grow from USD 4.3 billion in 2026 to USD 10.4 billion b...
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, pati...
Beyond the Breach: Taming the Hantavirus Threat with Favipiravir
While public health officials and hospital representatives are portraying Hantavirus pulmonary syndrome as being unassailable, waiting for a vaccine to arriv...
Etavopivat Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Etavopivat offers market opportunities by addressing unmet needs in sickle cell disease and other hemoglobinopathies through its novel PKR activating mechani...